FLSM
PVLA

Frazier Life Sciences Management’s Palvella Therapeutics PVLA Stock Holding History

Frazier Life Sciences Management’s Portfolio PVLA Stock Details PVLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$110M Buy
882,400
+160,000
+22% +$16.7M 2.83% 11
2025
Q4 		$75.6M Hold
722,400
– – 2.03% 13
2025
Q3 		$45.3M Hold
722,400
– – 1.36% 19
2025
Q2 		$16.3M Buy
722,400
+32,388
+5% +$760K 0.65% 32
2025
Q1 		$19.3M Buy
690,012
+36,120
+6% +$696K 0.88% 24
2024
Q4 		$7.85M Buy
653,892
+637,950
+4,002% +$10M 0.33% 40
2024
Q3 		$267K Buy
+15,942
New +$233K 0.01% 53

Other funds holding PVLA

SCM
Suvretta Capital Management New York $3.69B AUM 86.67% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return